SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives

Holly E Gurgle, Karen White, Carrie McAdam-Marx Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA Abstract: Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unabl...

Full description

Bibliographic Details
Main Authors: Gurgle HE, White K, McAdam-Marx C
Format: Article
Language:English
Published: Dove Medical Press 2016-06-01
Series:Vascular Health and Risk Management
Subjects:
type 2 diabetes mellitus
GLP-1 receptor antagonist
SGLT2 inhibitor
A1c
weight loss
adverse effect
Online Access:https://www.dovepress.com/sglt2-inhibitors-or-glp-1-receptor-agonists-as-second-line-therapy-in--peer-reviewed-article-VHRM

Internet

https://www.dovepress.com/sglt2-inhibitors-or-glp-1-receptor-agonists-as-second-line-therapy-in--peer-reviewed-article-VHRM

Similar Items